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Omid Mirshaﬁee, MD,* and Shahin Akhondzadeh, PhD*Objectives: Despite the burden of negative symptoms on quality of
life in schizophrenic patients, no completely effective treatment has been
developed to address such symptoms yet. Abnormalities in oxidative
stress pathways have been recently demonstrated to be involved in the
pathophysiology of schizophrenia, and a growing interest in antioxidant
agents is emerging for targeting negative symptoms of schizophrenia.
N-acetylcysteine (NAC) is a potent antioxidant with neuroprotective
properties. This study aimed to evaluate the possible effects of NAC as
an adjunct to risperidone in treating negative symptoms of schizophrenia.
Materials and Methods: In this randomized double-blind, placebo-
controlled, parallel-group study, 42 patients with chronic schizophrenia
with a score of 20 or greater on the negative subscale of positive and
negative syndrome scale (PANSS) were enrolled in the active phase of
their illness. The participants were equally randomized to receive NAC
(up to 2 g/d) or placebo, in addition to risperidone (up to 6 mg/d) for
8 weeks. The participants were rated using PANSS every 2 weeks, and
a decrease in PANSS negative subscale score was considered as our pri-
mary outcome.
Results: By the study end point, NAC-treated patients showed signiﬁ-
cantly greater improvement in the PANSS total (P = 0.006) and negative
subscale (P < 0.001) scores than that in the placebo group, but this dif-
ference was not signiﬁcant for positive and general psychopathology
subscales. There was no signiﬁcant difference between the 2 groups in
the frequency of adverse effects.
Conclusions: N-acetylcysteine add-on therapy showed to be a safe
and effective augmentative strategy for alleviating negative symptoms
of schizophrenia.Copyright @ 2013 Lippincott Williams & Wilk
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Negative symptoms in schizophrenia are characterized bydeﬁcits in normal emotion and social functions that can
be primary or secondary to the illness treatment or other man-
ifestations.1 These symptoms are strongly associated with long-
term disability tending to worsen over time and negatively affect
patient quality of life.2 Despite such burden, negative symptoms
are more resistant to treatment than the positive ones are and
present antipsychotics as incapable of relieving negative
schizophrenic symptoms.3 Because no fully effective treatment
for these symptoms has been developed yet, many researchers are
striving on to ﬁnd novel therapeutic agents on the basis of under-
lying defects in schizophrenia. Several lines of evidence suggest
that oxidative stress plays a key role in the pathophysiology of var-
ious neuropsychiatric disorders, and oxidative stress pathways
have recently attracted greater attention as promising novel tar-
gets for treating these disorders.4,5 Although numerous antioxi-
dant agents with different pharmacokinetic and pharmacodynamic
proﬁles are currently available, relatively few clinical trials have
been designed, to date, to evaluate their probable beneﬁcial effects
on disorders affecting the central nervous system and higher cor-
tical functions such as schizophrenia.
Glutathione (GSH) is one of the most important tissue
antioxidants in the brain, which is composed of glycine, cyste-
ine, and glutamate.6 Glutathione is the main endogenous antiox-
idant produced by cells and directly neutralizes free radicals and
reactive oxygen species.7 Glutathione system dysfunctions have
been illustrated in many neuropsychiatric disorders includ-
ing schizophrenia.8,9 Glutathione levels are decreased in blood
samples, cerebrospinal ﬂuid, and postmortem brains of schizo-
phrenic individuals.10–13 It has been demonstrated that GSH de-
pletion exacerbates schizophrenic symptoms through increased
oxidative stress and subsequent neuronal toxicity.14,15 Besides
its antioxidant and free radical scavenging properties, GSH can
modulate the glutamate N-methyl-D-aspartate receptor (NMDAR)
activity by decreasing oxidizing agents that bind to the redox-
sensitive site of NMDAR complexes.8,16 Glutathione deﬁcits in-
duce synaptic plasticity impairments and NMDAR hypofunction
in rats.17 The relationship between GSH and glutamate systems
is particularly interesting in light of proven underlying dysfunctions
of glutamate receptors and glutamatergic neurotransmission in
schizophrenia.18ins. Unauthorized reproduction of this article is prohibited.
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Farokhnia et al Clinical Neuropharmacology • Volume 00, Number 00, Month/Month 2013N-acetylcysteine (NAC), an acetylated derivative of amino
acid L-cysteine, is a GSH precursor with antioxidant, neuro-
tropic, and anti-inﬂammatory properties, along with modulatory
effects on dopaminergic and glutamatergic systems.19 Despite
oral GSH, which is rapidly metabolized by the liver and the
intestines and has poor penetration of the blood-brain barrier,
oral NAC is quickly absorbed from the alimentary tract, which
leads to increased GSH plasma levels, and crosses the blood-
brain barrier serving as a precursor for GSH synthesis in the
central neurons.20,21 Beneﬁcial neuroprotective effects of NAC
have been demonstrated in many preclinical and clinical stud-
ies.19,22,23 In a 6-month double-blind, placebo-controlled, random-
ized trial, Berk et al24 reported signiﬁcantly greater improvement
in negative symptoms of the schizophrenic individuals who re-
ceived NAC than that in the placebo-treated patients. In another
randomized, double-blind clinical trial with crossover design,
treatment with NAC signiﬁcantly improved mismatch negativity
(MMN) compared with placebo in the patients with schizophre-
nia.25 Moreover, low-dose add-on administration of NAC could
signiﬁcantly improve the symptoms in a young woman with
treatment-resistant schizophrenia.26 In addition to clinical improve-
ment, it has been recently shown that NAC can modulate electro-
encephalographic synchronization in patients with schizophrenia.27
Regarding the role of NAC in the oxidative balance and its bene-
ﬁcial regulatory effects on some impaired neurotransmission path-
waysin schizophrenia including glutamate, it can be hypothesized
that NAC would be of beneﬁt in schizophrenia, especially in alle-
viating the negative symptoms.19 Because of inadequate response
seen with current medications, there is a growing interest in ad-
junctive strategies with different agents for the treatment of
schizophrenia or, at least, improving its disabling symptoms. Al-
though some studies have shown the improvement of negative
symptoms in schizophrenia by NAC, there is no published study
regarding the short-term therapy with adjunctive NAC in negative
symptoms of patients with schizophrenia in the active phase.24
Therefore, we designed the present study to evaluate the efﬁcacy
and tolerability of NAC as an adjunctive therapy to risperidone
in the treatment of negative symptoms of patients with schizo-
phrenia and in the active phase.Q7
Q8MATERIALS AND METHODS
Trial Design
This was an 8-week, parallel-group, placebo-controlled,
double-blind clinical trial with equal randomization (1:1). The
trial protocol was registered at the Iranian Clinical Trials Regis-
try (IRCT201106031556N21; www.irct.ir). The study was ap-
proved by the institutional review board of Tehran University
of Medical Sciences and performed in accordance with the Dec-
laration of Helsinki and its subsequent revisions.
Participants
Inclusion Criteria
Male and female inpatients aged 18 to 50 years were eligi-
ble to participate in this study if they had a diagnosis of schizo-
phrenia based on the DSM IV-TR criteria, a minimum score of
60 on the PANSS, a score of 20 or greater on the PANSS nega-
tive subscale, and a minimum disease duration of 2 years
(chronic schizophrenia), in addition to being in the active phase
of their illness. Diagnosis was based on a Structured Clinical In-
terview for DSM-IV-TR Axis I Disorders (SCID) and was con-
ﬁrmed with chart review and senior physician interview.Copyright @ 2013 Lippincott Williams & Wilki
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We excluded patients with diagnosis of any other DSM-IV
psychiatric disorder on the basis of a structured diagnostic inter-
view. Patients with signiﬁcant depression, deﬁned as a score of
14 or greater on the 17-item Hamilton Depression Rating scale
(HDRS) or a score of 4 or greater on depression item of PANSS,
were also excluded from the study.28 Other exclusion criteria
were serious medical or neurological disorders, alcohol or sub-
stance (other than nicotine) dependence, mental retardation (in-
telligence quotient, <70), inability to communicate, history of
hypersensitivity to NAC or risperidone, pregnancy, lactation,
and hepatic or kidney disease. Women in reproductive age were
included only if they were using a reliable contraception method.
Patients were also excluded if they had received any oral antipsy-
chotic drug during the last week, any depot antipsychotic medica-
tion during the last month, or electroconvulsive therapy (ECT)
during the last 2 weeks before their enrollment. The participants
were not allowed to use antidepressants, mood stabilizers, sedat-
ing antihistamines, or other antipsychotics during the course of
this trial.
After a complete description of study details, written in-
formed consent was obtained from the eligible participant and/
or the legal representative. The patients were informed of their
right to withdraw from the project at any time without any neg-
ative effect on their relationship with health care providers.
Study Settings
This study was a multicenter clinical trial conducted from
July 2011 to February 2013 at 3 academic hospitals: Roozbeh
Hospital (Tehran University of Medical Sciences, Tehran, Iran),
Razi Hospital (University of Social Welfare and Rehabilitation
Sciences, Tehran, Iran), and Qods Hospital (Kurdistan Univer-
sity of Medical Sciences, Sanandaj, Iran). Each participant
was evaluated on 5 occasions: at the baseline/screening visit
and at weeks 2, 4, 6, and 8. There were no ethnical or regional
restrictions for participation because the patients were referred
from different regions of Iran to these referral hospitals and
were enrolled if the patient and his/her family could adhere to
the trial plan.
Intervention
Eligible participants were equally randomized into 2 groups
to receive either NAC ( AHexal Pharmaceutical, Germany) or pla-
cebo, in addition to risperidone (Risperdal; Janssen Pharmaceuticals),
which was administered to all patients. Starting dose of risper-
idone was 2 mg/d, which was increased weekly in increments
of 2 mg, on the basis of clinical response, to a maximum dose
of 6 mg/d (2 mg Atid). The NAC initial dosage was 1000 mg/d
(500 mg bid) for the ﬁrst week, followed by 2000 mg/d (1000 mg
bid) for the subsequent 7 weeks. The patients were not allowed to
receive any behavior intervention therapy during the course of
the trial.
Outcomes
The PANSS was the efﬁcacy assessment measure used in
this study, and the patients were rated using PANSS on the basis
of a structured clinical interview at baseline/screening session
and weeks 2, 4, 6, and 8. The PANSS is a 30-item rating scale
consisting of validated subscales to examine positive (7 items),
negative (7 items), and general psychopathological (16 items)
symptoms of schizophrenia. These 3 subscales are summed up
in the PANSS total score.29 The PANSS has been widely used for
measuring the severity of symptoms in patients with schizophrenians. Unauthorized reproduction of this article is prohibited.
© 2013 Lippincott Williams & Wilkins
Clinical Neuropharmacology • Volume 00, Number 00, Month/Month 2013 N-acetylcysteine as an Adjunct to Risperidone AQ9and has been applied in several studies in Iran.30–35 The raters
were previously involved in several trials of schizophrenia and
had good experience in implementing the PANSS. Four trained
raters were responsible for rating the patients with an inter-
reliablity of greater than 90% on PANSS total symptoms. The
HDRS was also ﬁlled at baseline and week 8 to assess changes
in depressive symptoms. This scale contains 17 questions (mea-
sured either on 5-point or 3-point scales) that evaluate the severity
of depression-related symptoms.28 The primary outcome of this
study was the difference in the decrease of PANSS negative sub-
scale score from baseline to the study end point (week 8) between
the 2 groups. The difference between the 2 study arms on other
PANSS subscales and the PANSS total score were considered as
secondary outcome measures.
Safety
A thorough physical examination was performed, and vital
signs were recorded at the screening session and each post-
baseline visit. The participants and the nurses were encouraged
to immediately inform the research team about any unexpected
symptom after entering the study. Adverse effects were recorded
by a psychiatry resident at weeks 1, 2, 4, 6, and 8 through open-
ended questioning, followed by a complete adverse effects
checklist. The adverse effects checklist was a 25-item question-
naire covering a broad range of complaints. To evaluate the pos-
sible extrapyramidal symptoms, the Extrapyramidal Symptoms
Rating scale (ESRS) (part 1: parkinsonism, dystonia, dyskine-
sia; sum of 11 items) was also administered at baseline and
weeks 1, 2, 4, 6, and 8.36 In case of encountering any adverse ef-
fect at any time, an expert psychiatrist was responsible to make
decisions regarding whether to continue treatment, decrease dosage,Copyright @ 2013 Lippincott Williams & Wilk
FIGURE 1. Flow diagram of the study.
© 2013 Lippincott Williams & Wilkinsor discontinue the drugs. The behavior appraisal and adverse
effects checklist were completed by independent raters.
Randomization
The random allocation method was used to randomly and
equally assign the participants to the NAC or the placebo group
in a 1:1 ratio. Randomization codes were generated by means of
Excel software by an independent person who was not involved
elsewhere in the research project. The assignments were kept in
sequentially numbered, sealed, opaque envelopes and were
opened sequentially only after participant details were written
on the envelope. The aluminum foil inside the envelope rendered
the envelope impermeable to intense light. Separate persons were
responsible for rating and random allocation of the patients.
Blinding
The participants, the nurses, and the physicians who re-
ferred the patients were all blind to the treatment assignments
as well as to the research investigators and the raters. Placebo
tablets and their ingredients were identical to NAC tablets in
shape, size, texture, color, taste, and odor. The study drugs were
packed in identical containers and were dispensed by an inves-
tigational drug pharmacist.
Statistical Methods and Sample Size
IBM SPSS Statistic 20 (IBM Corporation) was used for data
analysis. The mean score changes on PANSS, HDRS, and ESRS
from baseline to the study end point were compared between
the 2 groups using independent sample t test. The effect of time
and time × treatment interaction was assessed using the generalins. Unauthorized reproduction of this article is prohibited.
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TABLE 1. Baseline Characteristics of the Participants
Variable
N-acetylcysteine +
Risperidone
Placebo +
Risperidone
Sex, n (%)
Female 12 (57) 10 (48)
Male 9 (43) 11 (52)
Age, mean (SD), y 32.23 (6.12) 33.38 (6.97)
Marital status, n (%)
Single 18 (86) 15 (71)
Married 3 (14) 5 (24)
Divorced — 1 (5)
Level of education, n (%)
Illiterate 1 (5) —
Primary school 13 (61) 17 (80)
High school diploma 6 (29) 2 (10)
University degree 1 (5) 2 (10)
Smoking, n (%) 15 (71) 19 (90)
Duration of illness,
mean (SD), mo
83.23 (41.02) 88.95 (44.66)
Type of schizophrenia, n (%)
Paranoid 10 (47) 11 (53)
Residual 4 (19) 3 (14)
Disorganized 2 (10) 4 (19)
Undifferentiated 5 (24) 3 (14)
Prior antipsychotic
medications, n (%)
Risperidone 16 (76) 15 (21)
Halopridol 11 (52) 14 (67)
Fluphenazine 6 (29) 7 (33)
Olanzapine 6 (29) 3 (14)
Farokhnia et al Clinical Neuropharmacology • Volume 00, Number 00, Month/Month 2013linear model repeated measures considering the treatment
group (NAC vs placebo) as the between-subject factor and
the study measurements as the within-subject variables (time).
If the Mauchly test of sphericity was signiﬁcant, Greenhouse-
Geisser correction for degrees of freedom was used. Multiple lin-
ear regression analysis was used to predict the change in PANSS
negative subscale scores (as our primary outcome) by assigning
change in PANSS positive subscale, HDRS, and ESRS scores as
well as the treatment group. Categorical variables were described
in number (%); continuous variables, as mean (SD). Mean dif-
ferences (MDs) were reported as MD 95% conﬁdence intervals
(95% CI). A P value of less than 0.05 was considered statistically
signiﬁcant. On the basis of previous trials, we assumed a ﬁnal dif-
ference of 5 between the 2 groups on the PANSS negative sub-
scale with a standard deviation of 5, a power of 90%, a 2-sided
signiﬁcance level of 5%, and an attrition rate of 10%. Therefore,
a total sample size of 46 was calculated.
RESULTS
Participants
One hundred and twenty-one patients were screened for
the eligibility criteria, and 46 patients were randomized into 2
groups. Two patients from each group dropped out from the trial
before week 2 because of either withdrawal of consent or sub-
stance dependence. A total number of 42 patients (placebo, 21;
NAC, 21) completed the trial (Fig. 1). There was no signiﬁcant
difference between baseline characteristics of the patients, which
are summarized in Table 1. Mean (SD) dose of the risperidone ad-
ministered throughout the study was 4.20 (0.63) mg/d in the NAC
group and 4.15 (0.56) mg/d in the placebo group. Baseline
PANSS total and subscale scores were not signiﬁcantly different
between the 2 groups, as well as the baseline HDRS and ESRS
scores (Table 2).
Outcomes
Positive and Negative Syndrome Scale
The PANSS Negative Subscale
The NAC group showed signiﬁcantly greater improvement
in the negative symptoms than that in the placebo group by
the end of the trial (MD 95% CI, 6.61 [4.08–9.15]; t40 = 5.27;
P < 0.001). In repeated-measure analysis, the effect of time
was signiﬁcant (F1.95,78.15 = 170.62, P < 0.001). The behavior
of the 2 treatment groups was not similar across time as demon-
strated by a signiﬁcant effect for time × treatment interaction
(F1.95,78.15 = 16.64, P < 0.001) (Fig. 2). When the PANSS neg-
ative subscale change was predicted by multiple linear regres-
sion analysis, it was found that the treatment group (β = −0.64,
t = −5.23, P < 0.001) and the change in HDRS (β = 0.24,
t = 2.04, P = 0.04) were independent signiﬁcant predictors.
Changes in the PANSS positive subscale (β = 0.05, t = 0.42,
P = 0.67) and ESRS (β = 0.05, t = 0.43, P = 0.66) scores could
not signiﬁcantly predict the change in PANSS negative sub-
scale scores. Treatment group (NAC or placebo) was the stron-
gest predictor of any negative symptom changes over the
course of this trial.
The PANSS Positive Subscale
Reduction of the scores in the PANSS positive subscale
was not signiﬁcantly different between the 2 groups at the end
of the trial (MD 95% CI, −0.95 [−4.38 to 2.48]; t40 = −0.56;
P = 0.57). The results of repeated-measure analysis revealed aCopyright @ 2013 Lippincott Williams & Wilki
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not for time × treatment interaction (F2.56,102.49 = 0.90, P = 0.42),
showing that the behavior of the 2 groups was similar across time.
The PANSS General Psychopathology Subscale
No signiﬁcant difference was determined in the reduction
of PANSS general psychopathology subscale scores between
the 2 groups by week 8 (MD 95% CI, 6.00 [−0.28 to 12.28];
t40 = 1.93; P = 0.06]. The effect of time was signiﬁcant in the
repeated-measure analysis (F1.71,68.72 = 142.98; P < 0.001),
but the effect of time × treatment interaction was not signiﬁcant
(F1.71,68.72 = 2.99; P = 0.06), showing that the behavior of the
2 groups was similar across time.
The PANSS Total Score
At the study end point, the patients in the NAC group ex-
perienced signiﬁcantly greater improvement in the PANSS to-
tal scores than that in the placebo group (MD 95% CI, 11.66
[3.62 to 19.71]; t40 = 2.93; P = 0.006]. The results of the
repeated-measure analysis showed signiﬁcant effect for time
(F2.00,80.29 = 378.91, P < 0.001] and time × treatment interaction
(F2.00,80.29 = 5.48, P = 0.006).
The Hamilton Depression Rating Scale
There was no signiﬁcant difference between the 2 groups
in the HDRS score change from baseline to the study end point
(MD 95% CI, −0.04 [−0.48 to 0.39]; t40 = −0.21; P = 0.82).ns. Unauthorized reproduction of this article is prohibited.
© 2013 Lippincott Williams & Wilkins
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TABLE 2. Mean (SD) Scores of the 2 Groups on Different Study Measures
Measure Week
N-acetylcysteine +
Risperidone
Placebo +
Risperidone P
Time × Treatment
Interaction
PAQ10 ANSS Negative subscale,
mean (SD)
Week 0 27.38 (4.35) 27.28 (6.10) 0.95 P < 0.001
Week 2 23.80 (3.84) 25.58 (6.34) 0.21
Week 4 19.71 (3.59) 23.66 (6.96) 0.02
Week 6 17.61 (3.61) 21.85 (7.29) 0.02
Week 8 14.04 (2.51) 20.57 (7.99) 0.001
PANSS Positive subscale,
mean (SD)
Week 0 30.23 (3.68) 32.33 (5.48) 0.15 P = 0.42
Week 2 25.95 (3.59) 25.90 (4.99) 0.97
Week 4 21.04 (3.15) 21.09 (4.54) 0.96
Week 6 16.38 (2.06) 16.71 (3.56) 0.71
Week 8 12.19 (3.37) 13.33 (4.56) 0.36
PANSS General psychopathology
subscale, mean (SD)
Week 0 55.80 (8.36) 55.00 (6.13) 0.72 P = 0.06
Week 2 51.28 (8.52) 50.76 (5.89) 0.81
Week 4 43.47 (7.21) 44.14 (7.68) 0.77
Week 6 37.04 (6.98) 40.14 (8.29) 0.19
Week 8 31.09 (9.09) 36.28 (7.59) 0.05
PANSS Total score,
mean (SD)
Week 0 113.42 (9.05) 114.61 (10.09) 0.69 P = 0.006
Week 2 101.04 (10.44) 102.52 (7.83) 0.60
Week 4 84.23 (10.31) 88.90 (10.10) 0.14
Week 6 71.04 (9.00) 78.71 (12.20) 0.02
Week 8 57.33 (10.45) 70.19 (12.46) 0.001
HDRS, mean (SD) Week 0 8.28 (1.92) 8.09 (1.84) 0.74 P = 0.82
Week 8 8.14 (1.68) 7.90 (1.70) 0.65
ESRS, mean (SD) Week 0 1.00 (2.52) 0.90 (2.71) 0.90 P = 0.64
Week 1 3.80 (4.13) 5.19 (4.63) 0.31
Week 2 6.00 (7.28) 6.90 (4.54) 0.63
Week 4 4.09 (2.68) 5.76 (3.85) 0.11
Week 6 2.52 (2.50) 4.47 (3.95) 0.06
Week 8 1.71 (1.38) 2.95 (2.72) 0.07
FIGURE 2. Comparison of the negative subscale scores of
PANSS (mean [SD]) over time between the 2 study groups. The
asterisk symbol indicates P < 0.05.
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niﬁcant effect neither for time (F1.00,40.00 = 2.35, P = 0.13)
nor for time × treatment interaction (F1.00,40.00 = 0.04, P = 0.82].
Adverse Events
No serious adverse event or death was reported in this trial.
Other than extrapyramidal symptoms assessed by ESRS, 10 ad-
verse effects were observed over the course of the trial on the
basis of the adverse effects checklist. No signiﬁcant difference
was detected between the 2 groups in the frequency of adverse
effects (Table 3).
The Extrapyramidal Symptoms Rating Scale
There was no signiﬁcant difference in the ESRS score
changes from baseline to week 8 between the 2 study groups
(MD 95% CI, 1.33 [−0.70 to 3.37]; t40 = 1.31; P = 0.19). The
results of the repeated-measure analysis showed signiﬁcant ef-
fect for time (F2.96,118.70 = 16.29, P < 0.001), but the effect of
time × treatment interaction was not statistically signiﬁcant
(F2.96,118.70 = 0.54, P = 0.64) (Table 2).
DISCUSSION
In line with our hypothesis, we showed that NAC was ef-
fective and tolerable in treating the primary negative symptomsins. Unauthorized reproduction of this article is prohibited.
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TABLE 3. Frequency of the Adverse Effects in the
2 Study Groups
AQ11 Adverse Effect
N-acetylcysteine +
Risperidone
Placebo +
Risperidone P
Drowsiness, n (%) 7 4 0.48
Constipation, n (%) 4 3 1.00
Dizziness, n (%) 6 4 0.71
Vomiting, n (%) 5 2 0.40
Increased appetite, n (%) 4 4 1.00
Nausea, n (%) 6 3 0.45
Headache, n (%) 5 3 0.69
Dry mouth, n (%) 5 2 0.40
Increased blood
pressure, n (%)
4 1 0.34
Diarrhea, n (%) 6 3 0.45
Farokhnia et al Clinical Neuropharmacology • Volume 00, Number 00, Month/Month 2013of schizophrenia. In this study, the patients receivingNAC showed
signiﬁcantly better improvement in the PANSS total and negative
subscale scores, but there was no difference between the 2 groups
in the PANSS positive or general psychopathology subscales,
HDRS, or ESRS. Negative symptoms consist of those that are pri-
mary to schizophrenia and the so-called secondary negative
symptoms, which are secondary to other manifestations of schizo-
phrenia, as well as symptoms due to illness treatment.1 To inves-
tigate the pure effect of medications on negative symptoms in
clinical trials and to attribute the clinical response to improvement
of primary negative symptoms, changes in confounding factors
including positive, depressive, and extrapyramidal symptoms
should be minimal during the course of the trial.1,3 In the present
study, no signiﬁcant difference was detected in the positive, de-
pressive, and extrapyramidal symptoms between the 2 groups.
Hence, we can attribute the improvement of the negative
symptoms in the NAC group to the reduction of primary negative
symptoms. Moreover, we measured changes in extrapyramidal
symptoms throughout the study and could ﬁnd no signiﬁcant dif-
ference in the ESRS scores between the 2 groups. No serious ad-
verse effect was observed in the NAC group, and there was no
signiﬁcant difference between the 2 trial groups in this regard, fur-
ther supporting the safety proﬁle of NAC in these patients.
Several studies have investigated the beneﬁcial effects
of NAC on schizophrenic patients.22,24,25,27,37,38 Lavoie
et al22,24,25,27,37,38 investigated the efﬁcacy of NAC on cerebral
functioning by means of a particular type of auditory evoked
potentials called MMN, which is an indicator of deﬁcits in
NMDAR function. They showed that add-on NAC signiﬁcantly
improves MMN generation in patients with schizophrenia, im-
plicating GSH dysregulation and glutamatergic dysfunction
as potential therapeutic targets in schizophrenia.25 In another
randomized, double-blind, placebo-controlled trial, Berk et al
reported that 2 g/d add-on NAC can be helpful in alleviating
the schizophrenia-related symptoms during a 24-week period.
Compared with the results of our study, they showed signiﬁcant
improvement in PANSS general psychopathology subscale, in
addition to total and negative subscale scores. The mean differ-
ence of negative symptoms reduction by the end of week 24 be-
tween the 2 groups was less than 2 in their trial compared with
the mean difference of 6.61 in our study. Taken together, these
ﬁndings suggest that short-term therapy with adjunctive NAC
may have the same efﬁcacy as that of long-term therapy in the
treatment of negative symptoms of schizophrenia. ImprovementCopyright @ 2013 Lippincott Williams & Wilki
6 www.clinicalneuropharm.comof negative subscale scores was observed in that study without
any signiﬁcant change in positive symptoms, but unlike our
study, they also reported signiﬁcant improvement of akathisia
in the NAC group and suggested NAC as a neuroprotective
agent for treatment of extrapyramidal symptoms as well. Of
note, Berk et al24 studied the effect of NAC on patients with sta-
ble chronic schizophrenia, whereas the patients in our study
were in active phase of their illness (high degree of total psycho-
pathology; PANSS total score, >60). Therefore, the differences
between the results of the 2 studies on the improvement of neg-
ative symptoms with NAC therapy can be attributed to dif-
ferences in studied populations or study designs that warrant
further investigation to be clariﬁed.
There are several reasons to explain why NAC can be help-
ful in treating schizophrenia. N-acetylcysteine is an acetylated
derivative of amino acid L-cysteine. After an oral administra-
tion, NAC reaches brain glial cells and is then oxidized to cys-
tine, which enters the cells in exchange for glutamate, leading to
increased extracellular glutamate. The entered cystine is subse-
quently reduced to cysteine, acting as a GSH precursor and
resulting in increased GSH levels.21,23,39 Glutathione ultimately
acts as a potent antioxidant and decreases cellular damage by
scavenging reactive oxygen species.6,8,40 In addition to GSH
production enhancement, NAC itself has been shown to have di-
rect radical scavenging properties as well.41 This antioxidant
property of NAC is particularly interesting in light of increasing
evidence suggesting deﬁcits in oxidative defenses in schizo-
phrenia.42,43 Besides affecting the oxidative balance, NAC has
beneﬁcial regulatory effects on some impaired neurotransmis-
sion pathways in schizophrenia including glutamate and dopa-
mine. Glutathione directly potentiates brain NMDARs in the
brain and indirectly regulates the neuronal glutamate exchange
via cystine-glutamate antiporter.16,44,45 Moreover, NAC has
been shown to modulate the dopamine release from neuronal
terminals as well.46,47 The role of immune system dysregulation
and alteration in inﬂammatory responses has been implicated
in the pathophysiology of schizophrenia.48 At least a part of
NAC's favorable effects seems to be due to its anti-inﬂammatory
properties and reduction of inﬂammatory cytokines.23,49,50
The results of this study should be interpreted with caution
in light of its limitations. Small sample size and short observa-
tional period are the major limitations of our study and require
the results to be conﬁrmed in larger and more extended trials.
Although PANSS is widely accepted and applied for evaluat-
ing treatment effects in schizophrenia research, the application of
this tool limited our study to assessment of behavioral problems;
hence, we could not evaluate the possible effects of NAC on cog-
nitive functions in this study.29 In conclusion, the present study
showed that 8 weeks of NAC treatment as an adjunct to
risperidone is safe and has signiﬁcant beneﬁcial effects in treat-
ment of schizophrenia negative symptoms.REFERENCES
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